Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project

Journal of Clinical Oncology

Volumn 17, Issue 11, 1999, Pages 3522-3530

  Crino L ^a   Scagliotti, Giorgio V ^a   Ricci, S ^a   De Marinis, F ^a   Rinaldi, M ^a   Gridelli, C ^a   Ceribelli, A ^a   Bianco, R ^a   Marangolo, M ^a   Di Costanzo, F ^a   Sassi, M ^a   Barni, S ^a   Ravaioli, A ^a   Adamo, V ^a   Portalone, L ^a   Cruciani, G ^a   Masotti, A ^a   Ferrara, G ^a   Gozzelino, F ^a   Tonato, M ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; IFOSFAMIDE; MESNA; MITOMYCIN;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0032701095     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.11.3522     Document Type: Article

References (36)

1. Ginsberg RJ, Goldberg M, Waters PE: Surgery in non-small cell lung cancer, in Roth JA, Ruckdeschel JC, Weisenburger TH (eds): Thoracic Oncology (ed 2). Philadelphia. PA, W.B. Saunders Company, 1995, pp 124-146
2. Ihde DC: Chemotherapy of lung cancer. N Engl J Med 327:1434-1441, 1992
3. Bunn PA: The treatment of non-small cell lung cancer: Current perspectives and controversies, future directions. Semin Oncol 21:49-59, 1994
4. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311:899-909, 1995
5. Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European Multicentre Trial including 612 patients. J Clin Oncol 12:360-367, 1994
6. Crinò L, Clerici M, Figoli F, et al: Chemotherapy of advanced non-small cell lung cancer: A comparison of three active regimens - A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Ann Oncol 6:347-353, 1995
7. Ramanathan R, Belani CP: Chemotherapy for advanced non-small cell lung cancer: Past, present and future. Semin Oncol 24:440-454, 1997
8. Anderson H, Lund B, Bach P, et al: Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: A phase II study. J Clin Oncol 12:1821-1826, 1994
9. Gatzemeier U, Shepherd FA, Le Chevalier T, et al: Activity of gemcitabine in patients with non-small cell lung cancer: A multicenter, extended phase II study. Eur J Cancer 32A:243-248, 1996
10. Begbie SD, Hui R, Levi JA, et al: Initial experience with gemcitabine for non-small cell lung cancer in Australia. Proc Am Soc Clin Oncol 14:378, 1995 (abstr)
11. Abratt RP, Bezwoda WR, Falkson G, et al: Efficacy and safety profile of gemcitabine in non-small cell lung cancer: A phase II study. J Clin Oncol 12:1535-1540, 1994
12. Fukuoka M, Negoro S, Kudo S, et al: Late phase II study of LY 188011 (gemcitabine hydrochloride) in patients with non-small cell lung cancer. Jpn J Cancer Chemother 23:1825-1832, 1996
13. Yokoyama A, Nakai Y, Yoneda S, et al: A late phase II study of LY 188011 (gemcitabine hydrochloride) in patients with non-small cell lung cancer. Jpn J Cancer Chemother 23:1681-1688, 1996
14. Martin C, Lund B, Anderson H, et al: Gemcitabine: Once-weekly schedule active and better tolerated than twice-weekly schedule. Anticancer Drugs 7:351-357, 1997
15. Steward WP, Dunlop DJ, Dabouis G, et al: Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: Preliminary results. Semin Oncol 24:24-26, 1997 (suppl 8)
16. Abratt RP, Bezwoda WR, Goedhals L, et al: Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small cell lung cancer. J Clin Oncol 15:744-749, 1997
17. Crinò L, Scagliotti G, Marangolo M, et al: Cisplatin-gemcitabine combination in advanced non-small cell lung cancer: A phase II study. J Clin Oncol 15:297-303, 1997
18. Sandler AB, Ansari R, McClean J, et al: A Hoosier Oncology Group phase II study of gemcitabine plus cisplatin in non-small cell lung cancer. Proc Am Soc Clin Oncol 14:357, 1995 (abstr 1089)
19. Shepherd FA, Cormier Y, Burkes R, et al: Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. Semin Oncol 24:27-30, 1997 (suppl 8)
20. Anton A, Artal A, Carrato A, et al: Gemcitabine plus cisplatin in advanced NSCLC: Final phase II results. Proc Am Soc Clin Oncol 16:461a, 1997 (abstr 1656)
21. Peters GJ, Bergman AM, Ruiz van Haperen VW, et al: Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22:72-79, 1995 (suppl 11)
22. Bergman B, Aaronson NK, Ahmedzia S, et al: The EORTC QLQ-LC13: A modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 30A:625-642, 1994
23. Aaronson NK, Ahmedzia S, Bergman B, et al: The EORTC QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
24. World Health Organization: The WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization. 1979, p 48
25. Kaplan EL, Meier P: Nonparametric estimation of incomplete observations. J Am Stat Assoc 53:457-481, 1958
26. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139-144, 1998
27. Pocock S, Simon R: Sequential treatment assignment with balancing of prognostic factors in controlled clinical trials. Biometrics 31:103-115, 1975
28. Perez EA, Putney JD, Gandara DR: In vitro dose-response relationship to cisplatin in human non-small cell lung cancer cell lines. Proc Am Assoc Cancer Res 30:459, 1989 (abstr)
29. Gralla RJ, Casper ES, Kelsen DP, et al: Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lungs: A randomized trial investigating two doses schedules. Ann Intern Med 95:414-420, 1981
30. Klastersky J, Sculier JP, Ravez P, et al: A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung cancer. J Clin Oncol 4:1780-1786, 1986
31. Gandara DR, Crowley J, Livingston RB, et al: Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the Southwest Oncology Group. J Clin Oncol 12:873-878, 1993
32. Minotti V, Crinò L, Meacci ML, et al: Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer. Lung Cancer 20:93-98, 1998
33. Sandler A, Nemunaitis J, Dehnam C, et al: Phase III study of cisplatin with or without gemcitabine (G) in patients with advanced nonsmall cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17:454a, 1998 (abstr 1747)
34. Cardenal F, Paz Lòpez-Cabrenizo M, Anton A, et al: Randomized phase III study of gemcitabine plus cisplatin versus etoposide plus cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 17:12-17, 1999
35. Rinaldi M, Crinò L, Scagliotti G, et al: A new schedule of gemcitabine-cisplatin in advanced non small cell lung cancer (NSCLC) with two different cisplatin dose levels: A phase II randomized trial. Proc Am Soc Clin Oncol 17:470a, 1998 (abstr 1807)
36. Van Zandwijk N, Crinò L, Kramer GW, et al: Phase II study of gemcitabine (GEM) plus cisplatin (CIS) as induction regimen for patients with stage IIIA non-small cell lung cancer (NSCLC) by the EORTC Lung Cancer Cooperative Group (EORTC 08955). Proc Am Soc Clin Oncol 17:468a, 1998 (abstr 1799)